Psilocybin derived compositions and methods using same

Abstract

Described herein are formulations for treating, preventing, or ameliorating one or more of irritable bowel syndrome (IBS), rheumatoid arthritis (RA), fibromyalgia, post-traumatic stress disorder, PTSD, neuropathic pain, or symptoms associated with any of the foregoing. The formulations disclosed herein comprise a therapeutic dose of one more of psilocybin, psilocin, baeocystin, and norpsilocin. The formulations disclosed herein may also comprise one or more cannabinoids, such as cannabidiol (CBD), one or more psychobiotic compounds, such as Lactobacillus rhamnosus JB-1, one or more prebiotics, such as sorbitol or alginate, Hericium erinaceus or extract thereof, brain derived neurotrophic factor (BDNF), and a docosahexaenoic acid (DHA)-rich oil. Also described herein are methods utilizing the aforementioned compositions.

1 . An alkaloid composition comprising an alkaloid compound selected from the group consisting of psilocybin, psilocin, baeocystin, norpsilocin, and any combination thereof. 
     
     
         2 . The alkaloid composition of  claim 1 , wherein the alkaloid compound is psilocybin. 
     
     
         3 . The alkaloid composition of  claim 2 , wherein the alkaloid composition further comprising baeocystin. 
     
     
         4 . The alkaloid composition of  claim 2 , wherein the alkaloid composition further comprising norpsilocin. 
     
     
         5 . The alkaloid composition of  claim 1 , further comprising cannabidiol. 
     
     
         6 . The alkaloid composition of  claim 1 , wherein the alkaloid composition further consists of one selected from the group consisting of an erinacines, hericenones, cyanthane terpenes, extracts from  Hericium  mushroom, and any combination thereof. 
     
     
         7 . The alkaloid composition of  claim 1 , further comprising a psychobiotic. 
     
     
         8 . The alkaloid composition of  claim 7 , wherein the psychobiotic is  Lactobacillus rhamnosus.    
     
     
         9 . The alkaloid composition of  claim 1 , further comprising a prebiotic. 
     
     
         10 . The alkaloid composition of  claim 1 , further comprising one or more medicinal mushrooms or extracts thereof. 
     
     
         11 . The alkaloid composition of  claim 1 , further comprising docosahexaenoic acid. 
     
     
         12 . The alkaloid composition of  claim 1 , wherein the alkaloid composition is formulated as an oral formulation. 
     
     
         13 . A method of treating rheumatoid arthritis, comprising administering an alkaloid composition, wherein the alkaloid composition comprising an alkaloid compound selected from the group consisting of psilocybin, psilocin, baeocystin, norpsilocin, and any combination thereof. 
     
     
         14 . The method of  claim 13 , wherein the administering comprises a micro-dosing regimen. 
     
     
         15 . The method of  claim 13 , wherein the administering comprises a macro-dosing regimen. 
     
     
         16 . The method of  claim 13 , wherein the alkaloid composition is formulated as an oral formulation. 
     
     
         17 . A method of treating irritable bowel syndrome, comprising administering an alkaloid composition, wherein the alkaloid composition comprising an alkaloid compound selected from the group consisting of psilocybin, psilocin, baeocystin, norpsilocin, and any combination thereof. 
     
     
         18 . The method of  claim 17 , wherein the administering comprises a micro-dosing regimen. 
     
     
         19 . The method of  claim 17 , wherein the administering comprises a macro-dosing regimen. 
     
     
         20 . The method of  claim 17 , wherein the alkaloid composition is formulated as an oral formulation.